Home > Boards > US Listed > Medical - Drugs >

Phio Pharmaceuticals Corp (PHIO)

Add PHIO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/18/2019 7:38:28 PM - Followers: 130 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform


Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301


Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PHIO News: Additional Proxy Soliciting Materials (definitive) (defa14a) 10/15/2019 05:01:10 PM
PHIO News: Additional Proxy Soliciting Materials (definitive) (defa14a) 10/11/2019 04:24:32 PM
PHIO News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 10/02/2019 06:04:49 PM
PHIO News: Notice of Effectiveness (effect) 10/02/2019 06:00:58 AM
PHIO News: Securities Registration Statement (s-1) 10/01/2019 06:41:39 PM
#4801   "It took 6 months...but your .19 prediction was sabaidii2 10/18/19 07:38:28 PM
#4800   It took 6 months...but your .19 prediction was the submariner 10/15/19 01:14:53 PM
#4799   Each pre-funded warrant included in the pre-funded units 420man 10/01/19 06:52:14 PM
#4798   TOTAL SCAM imo as this CROOK walked with NGIN 09/17/19 05:21:07 PM
#4797   This essentially says the company is still at The Other Guy 08/26/19 03:37:41 PM
#4796   PHIO~~.3458 NEWS~~~Novel Targets for the Use of Self-Delivering m1999 08/15/19 07:50:00 AM
#4795   "higher high and higher low since 2019, it's sabaidii2 06/23/19 07:06:43 PM
#4794   Jon, The ONLY way a retail investor can make sabaidii2 06/21/19 08:17:43 PM
#4793   PHIO following the oncology research company template. The Other Guy 06/21/19 01:27:52 PM
#4792   From this: ''Phio’s lead candidate, RXI-762, is pursuing jondoeuk 06/19/19 07:53:53 PM
#4791   Company reports earnings and there is no mention The Other Guy 05/15/19 12:13:06 PM
#4790   Did PHIO go private? NASDAQ compliance is The Other Guy 05/14/19 09:50:29 AM
#4789   But, then again, there is that thing about stargazer123 05/05/19 04:50:21 PM
#4788   Agreed. Odds are 100 to 1 that the stargazer123 05/05/19 03:45:27 PM
#4787   "I also suffered a reverse split. But after sabaidii2 05/05/19 12:56:54 PM
#4786   I can understand your anger. I also suffered stargazer123 05/05/19 10:40:42 AM
#4785   Will NASDAQ grant PHIO another extension? The The Other Guy 04/30/19 04:53:36 PM
#4784   "higher high and higher low since 2019, it's sabaidii2 04/27/19 06:38:11 PM
#4783   higher high and higher low since 2019, it's Wallstreetwarriors 04/27/19 03:29:38 PM
#4782   "setting up for a nice run..." sabaidii2 04/27/19 03:15:57 PM
#4781   setting up for a nice run... Wallstreetwarriors 04/27/19 02:23:26 PM
#4780   "1$ for next week?" sabaidii2 04/03/19 09:59:34 PM
#4779   1$ for next week? Wallstreetwarriors 04/03/19 09:14:42 PM
#4778   Slimy, slimy, slimy... sabaidii2 04/02/19 10:59:46 PM
#4777   Np The Other Guy 04/02/19 06:42:12 PM
#4776   30:1 is what I remember the warrants to The Other Guy 04/02/19 06:41:55 PM
#4775   "30:1 but I could be mistaken" sabaidii2 04/02/19 03:01:35 PM
#4774   ty DRspin 04/02/19 01:43:10 PM
#4773   30:1 but I could be mistaken. The Other Guy 04/02/19 01:41:37 PM
#4772   Nice set up on the chart $PHIO $AVEO TechnoAnalyst 04/01/19 08:33:55 PM
#4771   anyone know the warrant conversion...warrants seem real thin? DRspin 04/01/19 01:29:23 PM
#4767   Nothole, I don’t want to dissuade you. I The Other Guy 03/31/19 06:25:43 PM
#4766   I don’t know much about Glycostem but looking The Other Guy 03/31/19 05:46:17 PM
#4765   "Buyers doing their own Laboratory Due Diligence in sabaidii2 03/31/19 04:09:17 PM
#4764   YES I HAVE LOST BIG BUT EACH TIME Nothole 03/31/19 02:20:09 PM
#4763   "I am a RXII/PHIO Shareholder since inception in sabaidii2 03/31/19 01:29:29 PM
#4762   Hi Sabadii, I am new to this board Nothole 03/31/19 10:09:00 AM
#4761   Call me cynical, but the hope that management The Other Guy 03/31/19 09:32:13 AM
#4760   Oh, and an underwriter selling $15 million of The Other Guy 03/31/19 09:15:45 AM
#4759   Unfortunately that Jan 7 slide is nearly three The Other Guy 03/31/19 09:11:15 AM
#4758   Nothole, I see you're a new investor to this sabaidii2 03/30/19 03:40:35 PM
#4757   Why a Reverse Split is unlikely this time: Nothole 03/30/19 01:42:07 PM
#4756   If PHIO Management wanted shareholders to forget about Nothole 03/30/19 11:19:37 AM
#4755   “The PHIO Management over the years has taken The Other Guy 03/30/19 10:59:01 AM
#4754   PHIO ready to P0P I am convinced Nothole 03/30/19 10:30:28 AM
#4753   Chart looking very Strong: Golden_Cross 03/28/19 06:32:10 PM
#4752   * * $PHIO Video Chart 03-28-2019 * * ClayTrader 03/28/19 05:46:12 PM
#4751   Two RS’s ago. Geert (former CEO) decided to The Other Guy 03/28/19 11:58:37 AM
#4750   Damn used to be $68 per share? ??..holy inouttrader 03/28/19 11:18:47 AM
#4749   Be great 1.50..when was that???..thanks inouttrader 03/28/19 11:17:32 AM